Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments
详细信息 查看全文
- 作者：Shekoufeh Nikfar (1) (2)
Abbas Kebriaeezadeh (1)
Rassoul Dinarvand (1)
Mohammad Abdollahi (1) (3)
Mohammad-Ali Sahraian (4)
David Henry (5)
Ali Akbari Sari (1) (6) - 关键词：Cost ; Effectiveness ; Decision analysis ; Economic evaluation ; Interferon beta ; Markov model ; Modeling ; Switching
- 刊名：DARU Journal of Pharmaceutical Sciences
- 出版年：2013
- 出版时间：December 2013
- 年：2013
- 卷：21
- 期：1
- 全文大小：287KB
- 参考文献：1. Disanto G, Morahan JM, Ramagopalan SV: Multiple sclerosis: risk factors and their interactions. / CNS Neurol Disord Drug Targets 2012,11(5):545-55. CrossRef
2. / Multiple sclerosis International federation. http://www.msif.org
3. Ahlgren C, Odén A, Lycke J: High nationwide prevalence of multiple sclerosis in Sweden. / Mult Scler 2011,17(8):901-08. CrossRef
4. Kurtzke JF: Multiple sclerosis in time and space-geographic clues to cause. / J Neurovirol 2000,6(2):S134-S140.
5. Yousefi Pour GA, Ali Reza Rasekhi AR: Multiple sclerosis: a risk factor analysis Iran. / Arch Iran Med 2002,5(3):191-93.
6. Kalanie H, Gharagozli K, Kalanie AR: Multiple sclerosis: report on 200 cases from Iran. / Mult Scler 2003, 9:36-8. CrossRef
7. Saadatnia M, Etemadifar M, Maghzi AH: Multiple sclerosis in Isfahan, Iran. / Int Rev Neurobiol 2007, 79:357-75. CrossRef
8. Hashemilar M, Savadi Ouskui D, Farhoudi M, Ayromlou H, Asadollahi A: Multiple sclerosis in East-Azerbaijan, north west Iran. / Neurol Asia 2011,16(2):127-31.
9. Abedini M, Habibi Saravi R, Zarvani A, Farahmand A: Epidemiology of Multiple sclerosis in Mazandaran in 2007 (in Persian). / J Mazand Univ Med Sci 2008,18(66):82-7.
10. Milo R, Kahana E: Multiple sclerosis: Geoepidemiology, genetics and the environment. / Autoimmun Rev 2010, 9:A387-A394. CrossRef
11. Sahraian MA, Khorramnia S, Ebrahim MM, Moinfar Z, Lotfi J, Pakdaman H: Multiple sclerosis in Iran: a demographic study of 8,000 patients and changes over time. / Eur Neurol 2010, 64:331-36. CrossRef
12. Etemadifar M, Janghorbani M, Shaygannejad V, Ashtari F: Prevalence of multiple sclerosis in Isfahan, Iran. / Neuroepidemiology 2006, 27:39-4. CrossRef
13. Elhami SR, Mohammad K, Sahraian MA, Eftekhar H: A 20-year incidence trend (1989-008) and point prevalence (March 20, 2009) of multiple sclerosis in Tehran, Iran: a population-based study. / Neuroepidemiology 2011,36(3):141-47. CrossRef
14. Nabavi M, Poorfarzam S, Ghasemi H: Epidemiology, clinical trend and prognosis of multiple sclerosis in 203 patients of MS clinic in Shahid Mostafa Khomeini hospital in 2002 (in Persian). / Tehran Univ Med J 2006,64(7):90-7.
15. Ghandehari K, Riasi HR, Nourian A, Boroumand AR: Prevalence of multiple sclerosis in north east of Iran. / Mult Scler 2010,16(12):1525-526. CrossRef
16. Ghabaae M, Qelichnia Omrani H, Roostaeizadeh M: Epidemiology of multiple sclerosis in Tehran: a three year study. / Tehran Univ Med J 2007,65(5):74-7.
17. Ale-Yasin H, Sarai A, Alaeddini F, Ansarian E, Lotfi J, Sanati H: Multiple sclerosis: a study of 318 cases. / Arch Iran Med 2002,5(1):24-7.
18. Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K: Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. / J Manag Care Pharm 2007,13(3):245-61.
19. Nuijten MJ, Hutton J: Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. / Value Health 2002,5(1):44-4. CrossRef
20. / Statistical center of Iran. http://www.amar.org.ir
21. Nikfar S, Rahimi R, Rezaie A, Abdollahi M: A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis. / Arch Med Sci 2010,6(2):236-44. CrossRef
22. Nikfar S, Rahimi R, Abdollahi M: A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type. / Clin Ther 2010,2(11):1871-888. CrossRef
23. Nikfar S, Rahimi R, Abdollahi M: A systematic review on the efficacy of interferon beta in relapsing remitting multiple sclerosis; comparison of different formulations. / Inter J Pharmacol 2010,6(5):638-44. CrossRef
24. Packer C, Simpson S, Stevens A: International diffusion of new health technologies: a ten-country analysis of six health technologies. / Int J Technol Assess Health Care 2006,22(4):419-28. CrossRef
25. / European medicines agency, EMEA. http://www.ema.europa.eu/ema/index
26. / United States of America Food and drug administration, US-FDA. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index
27. Palesh M, Jonsson PM, Jamshidi H, Wettermark B, Tomson G, Fredrikson S: Diffusion of interferon beta in Iran and its utilization in Tehran. / Pharmacoepidemiol Drug Saf 2008,17(9):934-41. CrossRef
28. / Iranian Food and Drug Organization. http://fdo.behdasht.gov.ir
29. Cheraghali AM: Biosimilars; a unique opportunity for Iran national health sector and national pharmaceutical industry. / Daru 2012,20(1):35. CrossRef
30. World Health Organization, WHO (Eds): In
31. Nikfar S, Kebriaeezadeh A, Majdzadeh R, Abdollahi M: Monitoring of National Drug Policy (NDP) and its standardized indicators; conformity to decisions of the national drug selecting committee in Iran. / BMC Int Health Hum Rights 2005,5(1):5. CrossRef
32. Abdollahiasl A, Nikfar S, Kebriaeezadeh A, Dinarvand R, Abdollahi M: A model for developing a decision support system to simulate national drug policy indicators. / Arch Med Sci 2011,7(5):744-46. CrossRef
33. Cheraghali AM, Nikfar S, Behmanesh Y, Rahimi V, Habibipour F, Tirdad R, Asadi A, Bahrami A: Evaluation of availability, accessibility and prescribing pattern of medicines in the Islamic Republic of Iran. / East Mediterr Health J 2004,10(3):406-15.
34. Nikfar S, Khatibi M, Abdollahiasl A, Abdollahi M: Cost and utilization study of antidotes: An Iranian experience. / Int J Pharmacol 2011,7(1):46-9. CrossRef
35. Nikfar S: A new model for decision analysis in economic evaluations of switchable health interventions. / J Med Hypotheses Ideas 2012, 6:12-5. CrossRef
36. Kobelt G, Jonsson L, Fredrikson S: Cost-utility of interferon beta1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis. / Eur J Health Econ 2003,4(1):50-9. CrossRef
37. Iskedjian M, Walker JH, Gray T, Vicente C, Einarson TR, Gehshan A: Economic evaluation of Avonex (interferon beta-1a) in patients following a single demyelinating event. / Mult Scler 2005,11(5):542-51. CrossRef
38. Bose U, Ladkani D, Burrell A, Sharief M: Cost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis: first estimates. / J Med Econ 2001, 4:207-19. CrossRef
39. Parkin D, McNamee P, Jacoby A, Miller P, Thomas S, Bates D: A cost-utility analysis of interferon beta for multiple sclerosis. / Health Technol Assess 1998,2(4):iii-54.
40. Phillips CJ, Gilmour L, Gale R, Palmer M: A cost utility model of beta-interferon in the treatment of relapsing-remitting multiple sclerosis. / J Med Econ 2001, 4:35-0. CrossRef
41. Chilcott J, McCabe C, Tappenden P, O'Hagan A, Cooper NJ, Abrams K, Claxton K, Miller DH, Cost Effectiveness of Multiple Sclerosis Therapies Study Group: Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. / BMJ 2003,326(7388):522. CrossRef
42. Briggs A, Claxton K, Sculpher M: Decision modelling for health economic evaluation. In / Handbooks in health economic evaluation. vol. 1 edition. Oxford: Oxford University Press; 2006.
43. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). / Neurology 1983,33(11):1444-452. CrossRef
44. Abdoli G: Estimation of social discount rate for Iran. / Eco Res Rev 2009, 10:135-56.
45. Robberstad B: Estimation of private and social time preferences for health in northern Tanzania. / Soc Sci Med 2005,61(7):1597-607. CrossRef
46. Baltussen R, Adam T, Tan Torres T, Hutubessy R, Acharya A, Evans DB, Murray CJL: Generalized cost-effectiveness analysis: a guide. In / World Health Organization. Global programme on evidence for health policy. Geneva: World Health Organization (WHO); 2002.
47. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC: The natural history of multiple sclerosis: a geographically-based study. I. Clinical course and disability. / Brain 1989, 112:133-46. CrossRef
48. Hirst C, Ingram G, Pearson O, Pickersgill T, Scolding N, Robertson N: Contribution of relapses to disability in multiple sclerosis. / J Neurol 2008,255(2):280-87. CrossRef
49. Hirst C, Swingler R, Compston DA, Ben-Shlomo Y, Robertson NP: Survival and cause of death in multiple sclerosis: a prospective population-based study. / J Neurol Neurosurg Psychiatry 2008, 79:1016-021. CrossRef
50. Whitehead SJ, Ali S: Health outcomes in economic evaluation: the QALY and utilities. / Br Med Bull 2010, 96:5-1. CrossRef
51. Tappenden P, Chilcott JB, Eggington S, Oakley J, McCabe C: Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-β and glatiramer acetate for multiple sclerosis. / Health Technol Assess 2004.,8(27): http://www.hta.ac.uk/fullmono/mon827.pdf
52. / National organization for civil registration: Survival data of Iran. http://www.sabteahval.ir
53. Tremlett H, Zhao Y, Devonshire V: Natural history of secondary-progressive multiple sclerosis. / Mult Scler 2008, 14:314-24. CrossRef
54. Tremlett H, Zhao Y, Devonshire V: Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. / J Neurol 2009, 256:374-81. CrossRef
55. European Study Group on interferon beta-1b in secondary progressive MS: Placebo-controlled multicentre andomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. / Lancet 1998,352(9139):1491-497. CrossRef
56. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group: Randomized controlled trial of interferon- beta-1a in secondary progressive MS: clinical results. / Clinical results. Neurology 2001,56(11):1496-504.
57. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE III, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, / et al.: Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). / Ann Neurol 1996,39(3):285-94. CrossRef
58. Panitch H, Miller A, Paty D, Weinshenker B, North American Study Group on Interferon beta-1b in Secondary Progressive MS: Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. / Neurology 2004,63(10):1788-795. CrossRef
59. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. / Lancet 1998,352(9139):1498-504. CrossRef
60. Andersen O, Elovaara I, F?rkkil? M, Hansen HJ, Mellgren SI, Myhr KM, Sandberg-Wollheim M, Soelberg S?rensen P: Multicenter, randomized, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. / J Neurol Neurosurg Psychiatry 2004,75(5):706-10. CrossRef
61. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ: Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. / Neurology 2003,60(1):44-1. CrossRef
62. The IFN, β Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. / Neurology 1993,43(4):655-61. CrossRef
63. Kappos L, Traboulsee A, Constantinescu C, Er?linna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D: Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. / Neurology 2006, 67:944-53. CrossRef
64. Ebers GC, Traboulsee A, Li D, Langdon D, Reder AT, Goodin DS, Bogumil T, Beckmann K, Wolf C, Konieczny A, Investigators of the 16-year Long-Term Follow-Up Study: Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. / J Neurol Neurosurg Psychiatry 2010, 81:907-12. CrossRef
65. Rudick RA, Lee JC, Cutter GR, Miller DM, Bourdette D, Weinstock-Guttman B, Hyde R, Zhang H, You X: Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up. / Arch Neurol 2010,67(11):1329-335. CrossRef
66. Phillips CJ: The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment. / CNS Drugs 2004,18(9):561-74. CrossRef
67. O’Brien B: / Multiple sclerosis. London: Office of Health Economics; 1987.
68. Tappenden P, Chilcott J, O'Hagan A, McCabe C: Cost effectiveness of beta interferons and glatiramer acetate in the management of multiple sclerosis. In / Final Report to the National Institute for Clinical Excellence. London: National Institute for Clinical Excellence (NICE); 2001.
69. Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, Kerrigan J: Cost-effectiveness analyses of natalizumab (Tysabri?) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. / PharmacoEconomics 2008,26(7):617-27. CrossRef
70. Iran ministry of health and medical education: / Tariff of healthcare services in public and private sectors in Iran (2012). Tehran: Iran ministry of health and medical education press; 2012.
71. / National Organization of Transportation. http://upto.ir
72. Koopmanschap MA, Rutten FFH, Van Ineveld BM, Van Roijen L: The friction cost method for measuring indirect costs of disease. / J Health Econ 1995, 14:171-89. CrossRef
73. Ganjali M, Baghfalaki T: Bayesian analysis of unemployment duration data in presence of right and interval censoring. / JRSS 2012,5(1):17-2.
74. Asian Productivity Organization: / APO productivity data book 2012. Tokyo: Keio university press INC; 2012.
75. Fisk JD, Brown MG, Sketris IS, Metz LM, Murray TJ, Stadnyk KJ: A comparison of health utility measures for the evaluation of multiple sclerosis treatments. / J Neurol Neurosurg Psychiatry 2005, 76:58-3. CrossRef
76. Strom BL, Kimmel SE: / Textbook of pharmacoepidemiology. Chichester, West Sussex: John Willey & Sons; 2006. CrossRef
77. Bobes J, Ca?as F, Rejas J, Mackell J: Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain. / Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:1287-297. CrossRef
78. Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM: Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. / J Manag Care Pharm 2009,15(7):543-55.
79. Fisk JD, Brown MG, Sketris IS, Metz LM, Murray TJ, Stadnyk KJ: A comparison of health utility measures for the evaluation of multiple sclerosis treatments. / J Neurol Neurosurg Psychiatry 2005,76(1):58-3. CrossRef
80. Kuspinar A, Rodriguez AM, Mayo NE: The effects of clinical interventions on health-related quality of life in multiple sclerosis: a meta-analysis. / Mult Scler 2012,18(12):1686-704. CrossRef
81. European Medicines Agency (EMEA)EMEA Guideline on Similar Biological Medicinal Products, CHMP/437/04. [http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf] EMEA Guideline on Similar Biological Medicinal Products, CHMP/437/04. [] - 作者单位：Shekoufeh Nikfar (1) (2)
Abbas Kebriaeezadeh (1)
Rassoul Dinarvand (1)
Mohammad Abdollahi (1) (3)
Mohammad-Ali Sahraian (4)
David Henry (5)
Ali Akbari Sari (1) (6)
1. Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
2. Food & Drug Organization, Ministry of Health & Medical Education, Tehran, Iran
3. Faculty of Pharmacy, and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran
4. Department of Neurology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
5. Institute for Clinical Evaluative Sciences, Toronto, Canada
6. Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran - ISSN：2008-2231
文摘
Background Multiple sclerosis (MS) is a highly debilitating immune mediated disorder and the second most common cause of neurological disability in young and middle-aged adults. Iran is amongst high MS prevalence countries (50/100,000). Economic burden of MS is a topic of important deliberation in economic evaluations study. Therefore determining of cost-effectiveness interferon beta (INF β) and their copied biopharmaceuticals (CBPs) and biosimilars products is significant issue for assessment of affordability in Lower-middle-income countries (LMICs). Methods A literature-based Markov model was developed to assess the cost-effectiveness of three INF βs products compared with placebo for managing a hypothetical cohort of patients diagnosed with relapsing remitting MS (RRMS) in Iran from a societal perspective. Health states were based on the Kurtzke Expanded Disability Status Scale (EDSS). Disease progression transition probabilities for symptom management and INF β therapies were obtained from natural history studies and multicenter randomized controlled trials and their long term follow up for RRMS and secondary progressive MS (SPMS). A cross sectional study has been developed to evaluate cost and utility. Transitions among health states occurred in 2-years cycles for fifteen cycles and switching to other therapies was allowed. Calculations of costs and utilities were established by attachment of decision trees to the overall model. The incremental cost effectiveness ratio (ICER) of cost/quality adjusted life year (QALY) for all available INF β products (brands, biosimilars and CBPs) were considered. Both costs and utilities were discounted. Sensitivity analyses were done to assess robustness of model. Results ICER for Avonex, Rebif and Betaferon was 18712, 11832, 15768 US Dollars ($) respectively when utility attained from literature review has been considered. ICER for available CBPs and biosimilars in Iran was $847, $6964 and $11913. Conclusions The Markov pharmacoeconomics model determined that according to suggested threshold for developing countries by world health organization, all brand INF β products are cost effective in Iran except Avonex. The best strategy among INF β therapies is CBP intramuscular INF β-1a (Cinnovex). Results showed that a policy of encouraging accessibility to CBPs and biosimilars could make even high technology products cost-effective in LMICs.